Technical Analysis for STOK - Stoke Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 11.43 | 1.42% | 0.16 |
STOK closed up 1.42 percent on Friday, November 22, 2024, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | 1.42% | |
| Down 3 Days in a Row | Weakness | 1.42% | |
| Down 4 Days in a Row | Weakness | 1.42% | |
| Down 5 Days in a Row | Weakness | 1.42% | |
| Oversold Stochastic | Weakness | 1.42% | |
| Lower Bollinger Band Walk | Weakness | 1.06% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Possible Inside Day | 1 day ago |
| Up 2% | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Down 1% | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50 percent of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke was launched with investments by Apple Tree Partners. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Precision Medicine Genetic Diseases Proteins Epigenetics Severe Genetic Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Precision Medicine Genetic Diseases Proteins Epigenetics Severe Genetic Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.58 |
| 52 Week Low | 3.77 |
| Average Volume | 578,991 |
| 200-Day Moving Average | 12.40 |
| 50-Day Moving Average | 12.73 |
| 20-Day Moving Average | 12.69 |
| 10-Day Moving Average | 12.48 |
| Average True Range | 0.70 |
| RSI (14) | 35.90 |
| ADX | 19.3 |
| +DI | 20.44 |
| -DI | 28.71 |
| Chandelier Exit (Long, 3 ATRs) | 12.63 |
| Chandelier Exit (Short, 3 ATRs) | 13.17 |
| Upper Bollinger Bands | 14.46 |
| Lower Bollinger Band | 10.92 |
| Percent B (%b) | 0.14 |
| BandWidth | 27.87 |
| MACD Line | -0.33 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.229 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.11 | ||||
| Resistance 3 (R3) | 12.09 | 11.84 | 11.99 | ||
| Resistance 2 (R2) | 11.84 | 11.67 | 11.85 | 11.95 | |
| Resistance 1 (R1) | 11.64 | 11.57 | 11.74 | 11.66 | 11.92 |
| Pivot Point | 11.39 | 11.39 | 11.45 | 11.40 | 11.39 |
| Support 1 (S1) | 11.19 | 11.22 | 11.29 | 11.21 | 10.94 |
| Support 2 (S2) | 10.94 | 11.12 | 10.95 | 10.91 | |
| Support 3 (S3) | 10.74 | 10.94 | 10.87 | ||
| Support 4 (S4) | 10.76 |
